1 active not recruiting, 1 terminated, 1 withdrawn. 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Active not recruiting 1, Terminated 1, Withdrawn 1 |
Follow Michael Choi: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Venetoclax With High-dose Ibrutinib for CLL Progressing on Single Agent Ibrutinib Venetoclax, Ibrutinib - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 1 | Active not recruiting | Michael Choi | 24 | 2018-05-01 | 2024-07-05 |
| Obinutuzumab With High-dose Ibrutinib for the Treatment of Patients With Chronic Lymphocytic Leukemia With Progressive Disease on Single Agent Ibrutinib. ibrutinib, obinutuzumab - Chronic Lymphocytic Leukemia | Phase 1 | Withdrawn | Michael Choi | 2016-06-01 | 2019-01-25 | |
| Dimethylfumarate (DMF) in Relapsed/Refractory CLL/SLL dimethyl fumarate - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 1 | Terminated | Michael Choi | 2 | 2016-06-01 | 2019-09-19 |
Leukemia, Lymphocytic, Chronic, B-Cell (3) · Neoplasms (3) · Disease Progression (1) · Recurrence (1)
ibrutinib (2) · Dimethyl Fumarate (1) · obinutuzumab (1) · venetoclax (1)
United States (2)